XP12B-MR Improves Activity Levels in Women With Heavy Menstrual Bleeding
NEW YORK (Reuters Health) May 06 - Women with heavy menstrual bleeding who were treated with the experimental agent XP12B-MR had significant improvements in physical, social and leisure activities, according to a presentation this week at the American College of Obstetrics & Gynecology annual clinical meeting in Chicago.
In a multicenter trial, Dr. Andrea Lukes at the Carolina Women's Research and Wellness Center in Chapel Hill, North Carolina, and colleagues randomized 187 women to receive either XP12B-MR (3.9 g/day for up to 5 days starting at the onset of heavy menstrual bleeding) or placebo.
Heavy menstrual bleeding was diagnosed using a validated alkaline hematin method, with a mean menstrual blood loss of 80 mL during two baseline cycles. Limitations on physical activities (walking, exercise, sports, etc.) and social or leisure activities (dancing, dining out, camping, etc.) during menstruation were assessed at baseline and over 6 menstrual cycles using two items on the validated Menorrhagia Impact Questionnaire (MIQ).
In the intent-to-treat analysis, mean scores were significantly reduced from baseline on both MIQ items in the XP12B-MR group compared with the placebo group, reflecting improvement in physical and social or leisure activities in treated women.
XP12B-MR was well tolerated, according to the researchers.
First Trimester Prenatal Screening
We are pleased to announce the availability of First Trimester Prenatal Screening. This major new innovation in screening called Early Screen involves the combination of a dried blood free Beta/PAPP-A laboratory test with an Ultrasound nuchal translucency measurement assessment. Nuchal Translucency/free Beta/PAPP-A is an option for all pregnant women. Early Screen detects chromosomal, heart (40%), and other fetal anomalies and perinatal risks. Our Ultrasound technician has received an NT certificate from the Fetal Medicine Foundation in London England. Patients may be referred for Early Screen evaluation between CRL 45 to 84mm which is 11w1d and 13w6d gestation. Our goal is to provide our patients the most advanced and accurate perinatal and genetic personalized care.
New Halo Breast Pap Test Offered
Women's Health Practice is the first in Illinois to offer a new noninvasive Halo Breast Pap Test that may identify breast disease years earlier than a mammogram or self exam. Keep an eye out for the Halo Breast Pap Test TV commercials. Click here for more info.